Business
Amneal Reports First Quarter 2026 Financial Results
‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒‒ Adjusted EBITDA of $202 million; Adjusted Diluted EPS of $0.27 ‒‒ No Change from Preliminary Results Previously Announced on April 22, 2026 ‒‒ Affirms Previously Announced Increase in 2026 Full Year Guidance ‒ BRIDGEWATER, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the first quarter ended Ma
About this update from Amneal Pharmaceuticals, Inc.
[{"type":"image","alt":"Amneal Pharmaceuticals LLC","displaySize":"","headline":null,"caption":"Amneal Pharmaceuticals LLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/3f58c6fb731aca69660cfd5331ef1107"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D5k2pDlH1.f72pOlfEh1mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/3f58c6fb731aca69660cfd5331ef1107","width":300,"height":89},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/D5k2pDlH1.f72pOlfEh1mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/3f58c6fb731aca69660cfd5331ef1107","width":300,"height":89}},"lazy":false},{"type":"text","content":"‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒‒ Adjusted EBITDA of $202 million; Adjusted Diluted EPS of $0.27 ‒‒ No Change from Preliminary Results Previously Announced on April 22, 2026 ‒‒ Affirms Previously Announced Increase in 2026 Full Year Guidance ‒","length":325,"tagName":"p"},{"type":"text","content":"BRIDGEWATER, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the first quarter ended March 31, 2026.","length":200,"tagName":"p"},{"type":"text","content":"“Amneal delivered a very strong start to 2026, reflecting the strength of our diversified business and multiple growth drivers across the portfolio. Our Specialty business continues to perform exceptionally well, led by CREXONT® and the recent launch of BREKIYA® autoinjector, alongside a strong cadence of key launches in Affordable Medicines. We are entering the Kashiv transaction from a position of strength, at a time when we see an extended period of accelerated growth ahead with no shortage of opportunities across our core businesses. Combined with our very strong first quarter results, we are pleased to affirm our previously announced increase in our full year 2026 guidance,” said Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal.","length":773,"tagName":"p"},{"type":"text","content":"First Quarter 2026 ResultsNet revenue in the first quarter of 2026 was $723 million, an increase of 4% compared to $695 million in the first quarter ...